GC Biopharma (006280 KS/Buy)2Q26 Preview: Earnings Set to Improve in 2H
We expect GC Biopharma to post below-consensus 2Q26 results, with revenue of W418.7bn (-16.3% YoY; vs. consensus of W473.6bn) and operating profit...
113 Views
GC Biopharma (006280 KS) Alyglo Performance Beats Expectations
For 1Q26, GC Biopharma reported revenue of W435.5bn (+13.5% YoY) and operating profit of W11.7bn (+47% YoY), in line with market expectations.
122 Views
GC Biopharma (006280 KS/Buy)4Q25 preview: Alyglo growth to ease concerns
We estimate that Alyglo revenue rose to around W70bn, supported by expanded prescriptions and inventory stocking, which likely contributed to...
138 Views
GC Biopharma (006280 KS/Buy)3Q25 Review: In-Line Results
For 3Q25, GC Biopharma posted revenue of W609.5bn (+31.1% YoY), beating the consensus (W520.2bn). Top-line growth was driven by: 1) higher sales of...
198 Views